雷米普利降低高血压房颤发生率以及改善左房内径的临床研究  

Retrospectively analysis of ramipril in decreasing risk of atrial fibrillation and inside diameter of left atrium in essential hypertension patients

作　　者：张大勇[1] 李德才[1] 蒋涛[1] 王庆旭[1] 刘思泰[1] 唐焕君[1] 舒艳[1] 王永春[1] 

机构地区：[1]川北医学院第二附属医院心内科,四川绵阳621000

出　　处：《中国现代医学杂志》2007年第16期2021-2023,共3页China Journal of Modern Medicine

摘　　要：目的探讨血管紧张素转换酶抑制剂(ACEI)雷米普利对高血压患者降低心房颤动(AF)发生率以及改善左房内径的影响。方法将180例原发性高血压患者分为雷米普利治疗组(90例)及苯磺酸氨氯地平治疗组(90例)。结果治疗50个月后雷米普利治疗组AF发生率3.4%,苯磺酸氨氯地平治疗组AF发生率为8.05%;治疗组左房内径缩小(2.0±1.5)mm,对照组左房内径缩小(0±1.6)mm。两组相比P<0.05,差异有显著性。结论雷米普利可降低高血压患者AF的发生率以及改善左房内径。[Objective] To study the effect of ramipril in decreasing the risk of atrial fibrillation and the inside diameter of left atrium in essential hypertension patient. [Methods] Essential hypertension patients were divided into ramipril group （n =90） and amlodipine group （n =90）. [Results] After 50 months, 3.4% patients in ramipril group and 8.05% patients in amlodipine group occurred AF （P 〈0.05）. The inside diameter of left atrium was reduced （2.0±1.5） mm in ramipril group and （0±1.6） mm in amlodipine group （P 〈0.05）. [Conclusion] Ramipril could decreas the risk of atrial fibrillation and the inside diameter of left atrium in essential hypertension patients.

关 键 词：血管紧张素转换酶抑制剂 雷米普利 高血压 心房颤动 左房内径 

分 类 号：R541.3[医药卫生—心血管疾病]